{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-337974","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2026-08-06T20:08:20+00:00","discovered_at":"2026-08-06T20:09:00.255357+00:00","generated_at":"2026-08-06T20:09:10.578280+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Therapeutics Q2 2026 net loss $17.8M; cash $318.9M; Phase 3 OCEAN-1 initiated","bullets":["Net loss of $17.8M in Q2 2026 vs $12.3M in Q2 2025; R&D expenses $15.2M (up from $9.4M).","Cash, cash equivalents and marketable securities $318.9M; April 2026 stock offering netted $162.3M; cash runway into 2030.","Initiated Phase 3 OCEAN-1 trial for IPF-related chronic cough; topline data expected H1 2028.","Initiated Phase 2b LAKE trial for refractory chronic cough; sample size re-estimation expected Q4 2026.","Submitted FDA meeting request for non-IPF ILD-related chronic cough development plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-337974","json":"https://secwatch.observer/filing/0001193125-26-337974.json","markdown":"https://secwatch.observer/filing/0001193125-26-337974.md","text":"https://secwatch.observer/filing/0001193125-26-337974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/0001193125-26-337974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:09:10.578280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}